Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free OACC Stock Alerts

Oaktree Acquisition Corp. III Life Sciences (OACC) Competitors

Oaktree Acquisition Corp. III Life Sciences logo
$10.74 0.00 (0.00%)
Closing price 08/28/2026 03:57 PM Eastern
Extended Trading
$10.77 +0.03 (+0.28%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

OACC vs. FSCO, RHLD, RPC, BBDC, and KBDC

Should you buy Oaktree Acquisition Corp. III Life Sciences stock or one of its competitors? Oaktree Acquisition Corp. III Life Sciences's main competitors and comparable companies include FS Credit Opportunities (FSCO), Resolute Holdings Management (RHLD), Ridgepost Capital (RPC), Barings Bdc (BBDC), and Kayne Anderson BDC (KBDC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does Oaktree Acquisition Corp. III Life Sciences compare to FS Credit Opportunities?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) and FS Credit Opportunities (NYSE:FSCO) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Oaktree Acquisition Corp. III Life Sciences had 3 more articles in the media than FS Credit Opportunities. MarketBeat recorded 3 mentions for Oaktree Acquisition Corp. III Life Sciences and 0 mentions for FS Credit Opportunities. Oaktree Acquisition Corp. III Life Sciences' average media sentiment score of 0.63 beat FS Credit Opportunities' score of 0.00 indicating that Oaktree Acquisition Corp. III Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Oaktree Acquisition Corp. III Life Sciences Positive
FS Credit Opportunities Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A
FS Credit Opportunities$137.77M7.60N/AN/AN/A

Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, FS Credit Opportunities has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Oaktree Acquisition Corp. III Life SciencesN/A N/A N/A
FS Credit Opportunities N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oaktree Acquisition Corp. III Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
FS Credit Opportunities
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

36.4% of FS Credit Opportunities shares are held by institutional investors. 0.3% of FS Credit Opportunities shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

FS Credit Opportunities beats Oaktree Acquisition Corp. III Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to Resolute Holdings Management?

Resolute Holdings Management (NYSE:RHLD) and Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Resolute Holdings Management has a beta of -1.29, meaning that its share price is 229% less volatile than the broader market. Comparatively, Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Resolute Holdings Management
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Oaktree Acquisition Corp. III Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Resolute Holdings Management has a net margin of 4.21% compared to Oaktree Acquisition Corp. III Life Sciences' net margin of 0.00%. Resolute Holdings Management's return on equity of 3.55% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Resolute Holdings Management4.21% 3.55% 1.71%
Oaktree Acquisition Corp. III Life Sciences N/A N/A N/A

Oaktree Acquisition Corp. III Life Sciences has lower revenue, but higher earnings than Resolute Holdings Management.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Resolute Holdings Management$462.05M2.29-$5.92M$5.4324.96
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A

In the previous week, Resolute Holdings Management had 9 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 12 mentions for Resolute Holdings Management and 3 mentions for Oaktree Acquisition Corp. III Life Sciences. Resolute Holdings Management's average media sentiment score of 1.48 beat Oaktree Acquisition Corp. III Life Sciences' score of 0.63 indicating that Resolute Holdings Management is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Resolute Holdings Management
9 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oaktree Acquisition Corp. III Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Resolute Holdings Management beats Oaktree Acquisition Corp. III Life Sciences on 6 of the 7 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to Ridgepost Capital?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) and Ridgepost Capital (NYSE:RPC) are both small-cap finance companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, Ridgepost Capital has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Ridgepost Capital has a net margin of 9.03% compared to Oaktree Acquisition Corp. III Life Sciences' net margin of 0.00%. Ridgepost Capital's return on equity of 21.02% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Oaktree Acquisition Corp. III Life SciencesN/A N/A N/A
Ridgepost Capital 9.03%21.02%9.21%

48.1% of Ridgepost Capital shares are owned by institutional investors. 11.8% of Ridgepost Capital shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Ridgepost Capital had 1 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 4 mentions for Ridgepost Capital and 3 mentions for Oaktree Acquisition Corp. III Life Sciences. Oaktree Acquisition Corp. III Life Sciences' average media sentiment score of 0.63 beat Ridgepost Capital's score of -0.50 indicating that Oaktree Acquisition Corp. III Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oaktree Acquisition Corp. III Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ridgepost Capital
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative

Ridgepost Capital has higher revenue and earnings than Oaktree Acquisition Corp. III Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A
Ridgepost Capital$297.35M3.23$19.50M$0.2534.80

Ridgepost Capital has a consensus price target of $13.00, indicating a potential upside of 49.43%. Given Ridgepost Capital's stronger consensus rating and higher probable upside, analysts plainly believe Ridgepost Capital is more favorable than Oaktree Acquisition Corp. III Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oaktree Acquisition Corp. III Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ridgepost Capital
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Ridgepost Capital beats Oaktree Acquisition Corp. III Life Sciences on 11 of the 12 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to Barings Bdc?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) and Barings Bdc (NYSE:BBDC) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Barings Bdc has a consensus target price of $9.75, indicating a potential upside of 4.28%. Given Barings Bdc's stronger consensus rating and higher probable upside, analysts clearly believe Barings Bdc is more favorable than Oaktree Acquisition Corp. III Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oaktree Acquisition Corp. III Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Barings Bdc
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20

Barings Bdc has a net margin of 32.73% compared to Oaktree Acquisition Corp. III Life Sciences' net margin of 0.00%. Barings Bdc's return on equity of 10.07% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Oaktree Acquisition Corp. III Life SciencesN/A N/A N/A
Barings Bdc 32.73%10.07%4.38%

44.1% of Barings Bdc shares are owned by institutional investors. 0.6% of Barings Bdc shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Barings Bdc had 1 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 4 mentions for Barings Bdc and 3 mentions for Oaktree Acquisition Corp. III Life Sciences. Barings Bdc's average media sentiment score of 1.12 beat Oaktree Acquisition Corp. III Life Sciences' score of 0.63 indicating that Barings Bdc is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oaktree Acquisition Corp. III Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Barings Bdc
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Barings Bdc has higher revenue and earnings than Oaktree Acquisition Corp. III Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A
Barings Bdc$279.21M3.51$101.92M$0.8311.27

Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, Barings Bdc has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Summary

Barings Bdc beats Oaktree Acquisition Corp. III Life Sciences on 12 of the 12 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to Kayne Anderson BDC?

Kayne Anderson BDC (NYSE:KBDC) and Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Kayne Anderson BDC has higher revenue and earnings than Oaktree Acquisition Corp. III Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kayne Anderson BDC$235.82M3.77$93.71M$1.0912.34
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A

Kayne Anderson BDC currently has a consensus price target of $14.88, indicating a potential upside of 10.59%. Given Kayne Anderson BDC's stronger consensus rating and higher possible upside, equities analysts clearly believe Kayne Anderson BDC is more favorable than Oaktree Acquisition Corp. III Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kayne Anderson BDC
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Oaktree Acquisition Corp. III Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Kayne Anderson BDC has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

Kayne Anderson BDC has a net margin of 31.54% compared to Oaktree Acquisition Corp. III Life Sciences' net margin of 0.00%. Kayne Anderson BDC's return on equity of 10.63% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kayne Anderson BDC31.54% 10.63% 5.06%
Oaktree Acquisition Corp. III Life Sciences N/A N/A N/A

In the previous week, Kayne Anderson BDC had 1 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 4 mentions for Kayne Anderson BDC and 3 mentions for Oaktree Acquisition Corp. III Life Sciences. Kayne Anderson BDC's average media sentiment score of 1.26 beat Oaktree Acquisition Corp. III Life Sciences' score of 0.63 indicating that Kayne Anderson BDC is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kayne Anderson BDC
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oaktree Acquisition Corp. III Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Kayne Anderson BDC beats Oaktree Acquisition Corp. III Life Sciences on 10 of the 10 factors compared between the two stocks.

Get Oaktree Acquisition Corp. III Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for OACC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OACC vs. The Competition

Export
MetricOaktree Acquisition Corp. III Life SciencesCapital Markets IndustryFinance SectorNASDAQ Exchange
Market Cap$263.99M$5.71B$14.01B$12.88B
Dividend YieldN/A7.39%5.88%11.27%
P/E RatioN/A32.7026.7425.45
Price / SalesN/A1,243.25518.00103.56
Price / CashN/A48.1530.4036.03
Price / BookN/A3.762.856.36
Net IncomeN/A$417.39M$1.31B$349.79M
7 Day PerformanceN/A0.69%0.27%-0.48%
1 Month Performance-0.28%2.27%2.54%4.17%
1 Year Performance2.68%6.00%10.76%15.11%

Oaktree Acquisition Corp. III Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OACC
Oaktree Acquisition Corp. III Life Sciences
N/A$10.74
flat		N/A+2.7%$263.99MN/AN/AN/A
FSCO
FS Credit Opportunities
N/A$5.12
-1.3%		N/A-30.9%$1.03B$163.59MN/AN/A
RHLD
Resolute Holdings Management
1.0993 of 5 stars		$127.54
-0.1%		N/A+105.1%$998.73M$1.12B23.525,620
RPC
Ridgepost Capital
4.1515 of 5 stars		$8.96
+2.3%		$11.00
+22.8%		N/A$988.85M$297.35M35.88180
BBDC
Barings Bdc
4.0855 of 5 stars		$9.42
+0.8%		$9.75
+3.6%		-5.6%$985.82M$99.76M11.3426

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OACC) was last updated on 8/31/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel